佰仁医疗(688198) - 2020 Q1 - 季度财报

Financial Performance - Operating revenue for the period was ¥23,662,427.99, representing a decrease of 24.68% year-on-year[11] - Net profit attributable to shareholders was ¥8,962,611.66, down 31.13% from the previous year[11] - Basic earnings per share decreased by 57.14% to ¥0.09 from ¥0.21 in the previous year[11] - The net profit attributable to shareholders decreased by 31.13% to ¥8,962,611.66 from ¥13,013,481.31, primarily due to a decline in operating income impacted by the pandemic[24] - Total operating revenue for Q1 2020 was ¥23,662,427.99, a decrease of 24.9% from ¥31,416,893.81 in Q1 2019[44] - Net profit for Q1 2020 was ¥8,907,998.48, down 31.6% from ¥12,962,901.65 in Q1 2019[46] - Total profit for Q1 2020 was ¥10,555,004.55, a decrease of 31.1% compared to ¥15,375,463.34 in Q1 2019[44] - Total comprehensive income for the first quarter of 2020 was CNY 9,525,613.13, compared to CNY 13,579,830.91 in the first quarter of 2019, representing a decrease of approximately 29.8%[53] Cash Flow - Net cash flow from operating activities was ¥2,246,169.28, a significant decline of 80.39% compared to the same period last year[11] - The net cash flow from operating activities dropped by 80.39% to ¥2,246,169.28 from ¥11,456,479.78, mainly due to a decrease in cash received from sales and services[26] - Net cash flow from operating activities for Q1 2020 was CNY 2,246,169.28, down 80.7% from CNY 11,456,479.78 in Q1 2019[56] - Cash inflow from operating activities totaled CNY 24,577,237.40, a decline of 23.8% compared to CNY 32,181,697.18 in the previous year[56] - Cash outflow from operating activities increased to CNY 22,331,068.12, up 7.8% from CNY 20,725,217.40 in Q1 2019[56] - The net increase in cash and cash equivalents for Q1 2020 was CNY 5,561,051.45, contrasting with a decrease of CNY 74,954,977.63 in Q1 2019[56] Assets and Liabilities - Total assets at the end of the reporting period reached ¥791,846,753.36, a 0.45% increase compared to the end of the previous year[11] - The total current assets amounted to ¥739,013,153.64, slightly up from ¥733,940,193.91 at the end of the previous year[29] - Total liabilities decreased to ¥18,034,263.89 from ¥23,387,232.91, indicating a decline of about 22.9%[33] - Current liabilities decreased to ¥17,013,361.86 from ¥21,384,752.46, a reduction of approximately 20.4%[32] - Owner's equity increased to ¥773,812,489.47 from ¥764,904,490.99, showing an increase of approximately 1.18%[33] - Non-current assets totaled ¥52,833,599.72, a decrease from ¥54,351,529.99, representing a decline of about 2.8%[32] Shareholder Information - The total number of shareholders at the end of the reporting period was 5,170[18] - The largest shareholder, Jin Lei, holds 62.42% of the shares, totaling 59,922,000 shares[18] Expenses and Investments - Research and development expenses accounted for 15.83% of operating revenue, an increase of 4.61 percentage points year-on-year[11] - The company's investment income increased significantly to ¥2,312,033.16 from ¥52,726.79, reflecting higher returns from bank wealth management and structured deposits[24] - Research and development expenses increased to ¥3,746,083.52 in Q1 2020 from ¥3,524,808.54 in Q1 2019, an increase of 6.3%[44] - The company reported a non-operating loss of ¥554,632.90 primarily due to donations of epidemic prevention materials[16] Other Financial Metrics - The weighted average return on net assets fell to 1.16%, a decrease of 5.25 percentage points compared to the previous year[11] - The company's financial expenses showed a significant increase in income, with a net figure of -¥482,209.45 compared to -¥29,587.26, mainly due to increased interest income from bank deposits[24] - Accounts receivable increased by 110.17% to ¥816,096.79 from ¥388,308.34, mainly due to an increase in credit sales[24] - Prepayments rose by 49.17% to ¥1,094,753.89 from ¥733,918.63, attributed to an increase in advance payments for materials[24] - The company's other current assets decreased by 69.22% to ¥1,028,836.07 from ¥3,342,869.92, primarily due to a reduction in other bank wealth management products that were not yet due[24] - The company's expected liabilities decreased by 85.17% to ¥170,902.03 from ¥1,152,480.45, mainly due to a reduction in sales rebates[24] - Cash and cash equivalents decreased to ¥469,943,305.11 from ¥708,287,182.90, a decline of about 33.6%[33] - Accounts payable increased to ¥4,832,911.06 from ¥4,447,658.40, reflecting an increase of approximately 8.7%[32] - Inventory increased to ¥11,698,705.06 from ¥10,680,965.94, representing a growth of about 9.5%[38]